Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 11/20 | 0.67 |
| ▸ | JAK2 | O60674 | 5/20 | 0.66 |
| ▸ | JAK3 | P52333 | 4/20 | 0.66 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.49 |
| ▸ | PAK3 | O75914 | 2/20 | 0.49 |
| ▸ | PAK2 | Q13177 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22535572 | 0.89 | NTRK1 (0.69) | NTRK1JAK2JAK3PAK1PAK3 | |
| SCHEMBL22535786 | 0.87 | NTRK1 (0.67) | NTRK1JAK2JAK3PAK1PAK3 | |
| SCHEMBL20575265 | 0.86 | NTRK1 (0.70) | NTRK1JAK2JAK3 | |
| SCHEMBL20575267 | 0.86 | NTRK1 (0.70) | NTRK1JAK2JAK3 | |
| SCHEMBL22535322 | 0.86 | JAK2 (0.66) | NTRK1JAK2JAK3 | |
| SCHEMBL22535809 | 0.86 | NTRK1 (0.76) | NTRK1JAK2JAK3PAK1PAK3 | |
| SCHEMBL20575168 | 0.84 | NTRK1 (0.53) | NTRK1JAK2JAK3PAK1PAK3 | |
| SCHEMBL22535423 | 0.84 | NTRK1 (0.53) | NTRK1JAK2JAK3PAK1PAK3 | |
| SCHEMBL22535434 | 0.84 | NTRK1 (0.53) | NTRK1JAK2JAK3PAK1PAK3 | |
| SCHEMBL22535321 | 0.84 | JAK2 (0.55) | NTRK1JAK2JAK3PAK1PAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800760-B2 | Trk inhibition | NANTBIO, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10800760-B2 | Trk inhibition | NANTBIO, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20180346450-A1 | TRK INHIBITION | NANTBIO, INC. | 2018-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346450-A1 | TRK INHIBITION | NTRK1, NTRK3, NTRK2 | NTRK1 1/4885JAK2 833/4885JAK3 649/4885 |
| US-10800760-B2 | Trk inhibition | NTRK1, NTRK3, NTRK2 | NTRK1 1/4885JAK2 833/4885JAK3 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.